JWJianping Wu

Jianping Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jianping Wu has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Qun Wang

    Department of Neurology, Beijing Tiantan Hospital, Capital Medical University

    13 shared publications
  • Ru Liu

    Department of Neurology, Beijing Tiantan Hospital Capital Medical University Beijing China

    12 shared publications
  • Qun Wang

    Beijing Tiantan Hospital, Capital Medical University, Beijing, 10070, China

    10 shared publications
  • Lei Sun

    Beijing Tiantan Hospital, Capital Medical University

    7 shared publications
  • Xi Guo

    Beijing Tiantan Hospital, Capital Medical University, Beijing 10070, China; China National Clinical Research Center for Neurological Diseases, Beijing 10070, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 10070, China

    7 shared publications
  • Aqeela Zahra

    Department of Pharmacology, School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, 440070, China

    6 shared publications

Latest Publications

  • Open Access

    Astrocyte‐Associated ABCA1/APOE Responses Accompany Hippocampal Lipid Remodeling and Ectopic Neuronal Accumulation During Epileptogenesis

    by Lu Chen, Xiao‐Rui Shi, Jia‐Yi Chen, Ying‐Ting Wang, Le Du, Yang Ni, Jun‐Min Chen, An‐Chen Guo, Qian Wu, Jian‐Ping Wu, et al.

    Temporal lobe epilepsy (TLE) is characterized by progressive hippocampal remodeling, including reactive astrogliosis and aberrant neuronal positioning. Although lipid disturbances are implicated in epileptogenesis, how astrocyte‐associated lipid responses relate to hippocampal remodeling remains poorly understood. Here, human TLE and kainic acid (KA)‐treated mouse transcriptomic datasets identified ATP‐binding cassette transporter A1 (ABCA1)/Abca1 as a nominal astrocyte‐associated candidate, while KA‐ and pilocarpine‐induced status epilepticus (SE) elicited astrocyte‐associated ABCA1/apolipoprotein E (APOE) responses. Ectopic granule cells and immature neurons accumulated in the hilus and were spatially associated with ABCA1‐positive cells, including astrocytic profiles; perilipin 2 (PLIN2)‐positive puncta were nearby. Pretreatment with the retinoid X receptor (RXR) agonist bexarotene increased hippocampal ABCA1 expression, delayed severe KA‐induced behavioral seizure onset, and was associated with fewer chronic spontaneous seizures and reduced ectopic neuronal accumulation. Post‐SE bexarotene administration was associated with lower seizure frequency, ectopic neuronal accumulation, and astrocytic marker‐positive cell densities. Multi‐omic profiling identified bexarotene‐associated metabolic and lipidomic changes; transmission electron microscopy (TEM) showed a smaller mean hilar neuronal lipid‐droplet area per image, and protein analyses identified early changes in p38 and extracellular signal‐regulated kinase 1/2 (Erk1/2) phosphorylation. Together, these findings warrant further investigation of astrocyte‐associated lipid pathways as potential therapeutic targets in epilepsy‐associated hippocampal remodeling.

  • Open Access

    Mechanisms and Therapeutic Targets of Ischemia—Reperfusion Injury in Stroke: A Narrative Review Focusing on Blood—Brain Barrier Dysfunction

    by Suqin Guo, Rui Liu, Si Cheng, Xia Liu, Jianping Wu

    Ischemic stroke remains a leading cause of death and disability worldwide. While thrombolysis and endovascular thrombectomy are current mainstays of treatment, their clinical efficacy is often undermined by ischemia–reperfusion injury (I/R). This injury induces secondary brain damage, primarily via disruption of the blood–brain barrier (BBB). No approved therapies directly target BBB protection. This review reinterprets the pathophysiological mechanism of BBB disruption after stroke through a dynamic spatiotemporal framework. The pathological cascade reaction is clearly divided into two core stages: the ischemic phase is mainly driven by energy failure and calcium overload; the reperfusion phase is further divided into four consecutive and progressive sub-stages, namely, oxidative stress burst, amplification of inflammatory response, matrix metalloproteinase 9 (MMP-9)-mediated barrier degradation and programmed cell death. This review critically assesses current therapies and identifies major clinical translation gaps, including a temporal mismatch between preclinical and clinical windows, unacceptable toxicity, lack of durable efficacy and biphasic effects. Matching specific interventions to the different pathophysiological stages of blood–brain barrier disruption is essential for optimizing clinical outcomes.


  • Open Access

    Unraveling the mechanisms of slack channel mutations in epileptic disorders

    by Yue Wei, Aqeela Zahra, Qun Wang, Jianping Wu

    Sodium-activated potassium channels (K Na ) are extensively expressed throughout the central nervous system (CNS) and play a pivotal role in modulating neuronal excitability. The K Na achieve this by regulating the threshold for action potential initiation and the magnitude of post-hyperpolarization. The KCNT1 gene encodes the α subunit of K Na , also known as Slack channel, is crucial for governing the membrane excitability of neurons. Mutations in the KCNT1 gene impair the function of these potassium channels, leading to seizures and a spectrum of epileptic disorders. These conditions are often intractable and can range in severity from moderate to profound. This article delves into the subject of Slack channel detailing their architecture, physiological functions, distribution, and expression patterns, as well as their essential role in the nervous system. Additionally, we address the topic of epilepsy resulting from mutations in the KCNT1 gene and the therapeutic strategies currently available for managing these challenging conditions.


  • Open Access

    Microbiota-derived IPA mitigates post-stroke neuroinflammation by inhibiting TREM2-dependent pyroptosis

    by Jun-Min Chen, Cong Zhang, Lu-Lu Yu, Jian-Xu Sun, Jiang-Hao Zhang, Lu Chen, Fei Zhu, Guang Shi, Lan Yang, An-Chen Guo, et al.

    Ischemic stroke remains the leading cause of long-term disability globally, underscoring the urgent need for novel therapeutic strategies. Here, we explore


  • Open Access

    3‐HKA Promotes Vascular Remodeling After Stroke by Modulating the Activation of A1/A2 Reactive Astrocytes

    by Jun‐Min Chen, Guang Shi, Lu‐Lu Yu, Wei Shan, Jing‐Yu Sun, An‐Chen Guo, Jian‐Ping Wu, Tie‐Shan Tang, Xiang‐Jian Zhang, Qun Wang

    Ischemic stroke is the most common cerebrovascular disease and the leading cause of permanent disability worldwide. Recent studies have shown that stroke development and prognosis are closely related to abnormal tryptophan metabolism. Here, significant downregulation of 3‐hydroxy‐kynurenamine (3‐HKA) in stroke patients and animal models is identified. Supplementation with 3‐HKA improved long‐term neurological recovery, reduced infarct volume, and increased ipsilateral cerebral blood flow after distal middle cerebral artery occlusion (MCAO). 3‐HKA promoted angiogenesis, functional blood vessel formation, and blood‐brain barrier (BBB) repair. Moreover, 3‐HKA inhibited A1‐like (neurotoxic) astrocyte activation but promoted A2‐like (neuroprotective) astrocyte polarization. Proteomic analysis revealed that 3‐HKA inhibited AIM2 inflammasome activation after stroke, and co‐labeling studies indicated that AIM2 expression typically increased in astrocytes at 7 and 14 days after stroke. Consistently, in co‐cultures of primary mouse brain microvascular endothelial cells and astrocytes, 3‐HKA promoted angiogenesis after oxygen‐glucose deprivation (OGD). AIM2 overexpression in astrocytes abrogated 3‐HKA‐driven vascular remodeling in vitro and in vivo, suggesting that 3‐HKA may regulate astrocyte‐mediated vascular remodeling by impeding AIM2 inflammasome activation. In conclusion, 3‐HKA may promote post‐stroke vascular remodeling by regulating A1/A2 astrocyte activation, thereby improving long‐term neurological recovery, suggesting that supplementation with 3‐HKA may be an efficient therapy for stroke.


  • Advances in research on metabolic dysfunction-associated steatotic liver disease

    by Jiawang Wang, Zhongyu Wang, Yao Yu, Si Cheng, Jianping Wu


  • Open Access

    Inhibiting acid‐sensing ion channel exerts neuroprotective effects in experimental epilepsy via suppressing ferroptosis

    by Xiaorui Shi, Ru Liu, Yingting Wang, Tingting Yu, Kai Zhang, Chao Zhang, Yuyu Gu, Limin Zhang, Jianping Wu, Qun Wang, et al.

    Background: Epilepsy is a chronic neurological disease characterized by repeated and unprovoked epileptic seizures. Developing disease‐modifying therapies (DMTs) has become important in epilepsy studies. Notably, focusing on iron metabolism and ferroptosis might be a strategy of DMTs for epilepsy. Blocking the acid‐sensing ion channel 1a (ASIC1a) has been reported to protect the brain from ischemic injury by reducing the toxicity of [Ca 2+ ] i . However, whether inhibiting ASIC1a could exert neuroprotective effects and become a novel target for DMTs, such as rescuing the ferroptosis following epilepsy, remains unknown. Methods: In our study, we explored the changes in ferroptosis‐related indices, including glutathione peroxidase (GPx) enzyme activity and levels of glutathione (GSH), iron accumulation, lipid degradation products‐malonaldehyde (MDA) and 4‐hydroxynonenal (4‐HNE) by collecting peripheral blood samples from adult patients with epilepsy. Meanwhile, we observed alterations in ASIC1a protein expression and mitochondrial microstructure in the epileptogenic foci of patients with drug‐resistant epilepsy. Next, we accessed the expression and function changes of ASIC1a and measured the ferroptosis‐related indices in the in vitro 0‐Mg 2+ model of epilepsy with primary cultured neurons. Subsequently, we examined whether blocking ASIC1a could play a neuroprotective role by inhibiting ferroptosis in epileptic neurons. Results: Our study first reported significant changes in ferroptosis‐related indices, including reduced GPx enzyme activity, decreased levels of GSH, iron accumulation, elevated MDA and 4‐HNE, and representative mitochondrial crinkling in adult patients with epilepsy, especially in epileptogenic foci. Furthermore, we found that inhibiting ASIC1a could produce an inhibitory effect similar to ferroptosis inhibitor Fer‐1, alleviate oxidative stress response, and decrease [Ca 2+ ] i overload by inhibiting the overexpressed ASIC1a in the in vitro epilepsy model induced by 0‐Mg 2+ . Conclusion: Inhibiting ASIC1a has potent neuroprotective effects via alleviating [Ca 2+ ] i overload and regulating ferroptosis on the models of epilepsy and may act as a promising intervention in DMTs.


  • Open Access

    Recent Advances in the Therapeutic Potential of Sinomenine for Cancer Treatment

    by PanZhen Jiang, Aqeela Zahra, Xi Guo, Jianping Wu

    Background: Cancer is a major cause of death worldwide. Although modern medicine has made strides in treatment, a complete cure for cancer remains elusive. Summary: Utilization of medicinal plants in traditional medicine for the treatment of multiple diseases, including cancer, is a well-established practice. Sinomenine is an alkaloid extracted from a medicinal plant and has a diverse range of biological properties, including anti-oxidative, anti-inflammatory, and antibacterial effects. Sinomenine exhibits inhibitory effects on various types of tumor cells, including breast, lung, and liver cancers. The anticancer properties of sinomenine are believed to involve stimulation of apoptosis and autophagy as well as suppression of cell proliferation, invasion, and metastasis. Key Message: This review summarizes the current research on sinomenine’s potential as an anticancer agent, which may contribute to the discovery of more effective cancer treatments.